AIT Therapeutics (OTCMKTS: AITB) is one of 104 public companies in the “Surgical & medical instruments” industry, but how does it compare to its peers? We will compare AIT Therapeutics to similar companies based on the strength of its profitability, analyst recommendations, valuation, risk, earnings, institutional ownership and dividends.
Institutional & Insider Ownership
47.6% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 15.3% of shares of all “Surgical & medical instruments” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares AIT Therapeutics and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|AIT Therapeutics||N/A||-$18.04 million||-1.00|
|AIT Therapeutics Competitors||$1.54 billion||$111.80 million||-138.94|
AIT Therapeutics’ peers have higher revenue and earnings than AIT Therapeutics. AIT Therapeutics is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
This is a breakdown of current recommendations and price targets for AIT Therapeutics and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|AIT Therapeutics Competitors||500||1894||3762||118||2.56|
AIT Therapeutics presently has a consensus target price of $16.00, suggesting a potential upside of 433.33%. As a group, “Surgical & medical instruments” companies have a potential upside of 16.37%. Given AIT Therapeutics’ stronger consensus rating and higher possible upside, research analysts clearly believe AIT Therapeutics is more favorable than its peers.
This table compares AIT Therapeutics and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|AIT Therapeutics Competitors||-61.87%||-46.33%||-17.63%|
About AIT Therapeutics
AIT Therapeutics, Inc., a biopharmaceutical company, engages in developing a single proprietary formulation of 160 parts per million of nitric oxide and delivery systems to treat respiratory infections. The company's pipeline includes therapies against respiratory infections in acute and chronic diseases, such as severe bronchiolitis (RSV), cystic fibrosis related lung infections (CF), and non-tuberculosis mycobacterial (NTM) infections. It has completed two Phase II trials to treat RSV and CF related lung infections, as well as conducted a treatment for patients with CF who suffer from NTM infections. The company was founded in 2011 and is based in Ness Ziona, Israel.
Receive News & Ratings for AIT Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AIT Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.